|Bid||5.470 x 0|
|Ask||5.530 x 0|
|Day's Range||5.410 - 5.550|
|52 Week Range||4.580 - 9.600|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||18.52|
|Forward Dividend & Yield||0.06 (0.99%)|
|1y Target Est||10.20|
Since Essex Bio-Technology Limited (HKG:1061) released its earnings in June 2018, analysts seem fairly confident, with profits predicted to increase by 21% next year, though this is relatively lower than Read More...
If you want to know who really controls Essex Bio-Technology Limited (HKG:1061), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in Read More...
July 16 (Reuters) - Essex Bio-Technology Ltd: * ESSEX BIO-INVESTMENT AGREED TO FUND MAXIMUM OF US$16.5 MILLION FOR CLINICAL DEVELOPMENT IN U.S. FDA FIRST PHASE 3 CLINICAL TRIAL * UNDER AGREEMENT, ESSEX ...